{
    "nct_id": "NCT06107413",
    "official_title": "A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Diagnosis of histologically or cytologically confirmed unresectable metastatic colorectal cancer (mCRC).\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Harbor the BRAF V600E mutation.\n* dMMR+/MSI-H.\n* Progressed on only one first-line (1L) systemic treatment of combination chemotherapy in the metastatic setting with or without targeted therapy.\n* Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400.",
    "miscellaneous_criteria": ""
}